AFMD News and Press, Affimed N.V. From 04/19/21

In an increasingly saturated landscape of immune oncology companies, Affimed presents a new solution through innate NK cell therapies designed to fight relapsed cancers. Affimed’s core technology has garnered corporate interest in the sector, leading to immune oncology partners...

Affimed's wholly-owned pipeline programs continue to report impressive clinical data that supports a long-term investment. I believe is Affimed is trailblazing on a new approach in oncology. The company's three-pronged approach of testing their products as a monotherapy, NK combo, and...

The first week of AACR 2021 (American Association of Cancer Research Annual Meeting) has concluded with Affimed (AFMD) emerging as a clear winner while iTeos Therapeutics (ITOS) disappointed with an early-stage study for its lead asset.The presentations from Eli Lilly (LLY), Oncternal Therape...

On Thursday, drugmaker Affimed N.V. (NASDAQ: AFMD) released its earnings report for the fiscal year 2020, which ended on Dec. 31. Investors were not pleased with the company's financial results, however, and its shares fell sharply as a result. Affimed's stock ended the day down by ...

Affimed N.V. (AFMD) Q4 2020 Earnings Conference Call April 15, 2021 08:30 ET Company Participants Alexander Fudukidis - Head, Investor Relations Adi Hoess - Chief Executive Officer Angus Smith - Chief Financial Officer Andreas Harstrick - Chief Medical Officer Denise Mueller - Chief Business ...

Affimed ([[AFMD]] -7.8%) FY results:Revenue of €28.4M (+32.7% Y/Y).Operating Loss: (€34.72M) (-7.23%); Net Loss: (€41.37M) (-27.80%); Loss Per Share: (€0.50) (flat Y/Y).Quick Assets: €146.9M, with anticipated cash runway into 2H...

Gainers: Ardelyx (ARDX) +13%, Liquidia (LQDA) +9%, PPD (PPD) +7%, Inovio Pharmaceuticals (INO) +6%, BiomX (PHGE) +6%.Losers: Zomedica (ZOM) -12%, Affimed (AFMD) -10%, Aesthetic Medical International (AIH) -7%, Galectin Therapeut...

Affimed (AFMD): FY GAAP EPS of -€0.50 misses by €0.48.Revenue of €28.4M (+32.7% Y/Y) beats by €12.81M.Press Release For further details see: Affimed EPS misses by €0.48, beats on revenue

Affimed (AFMD) announces pre-clinical data on its Innate Cell Engager ((ICE)) AFM24 as monotherapy and in combination with adoptively transferred NK cells at AACR Meeting 2021. AFM24 induces NK cell-mediated antibody-dependent cellular cytotoxicity ((ADCC)) against EGFR-expressing tumor cells...

AFM24 induces strong tumor cell killing independent of KRAS mutations AFM24, in combination with adoptive NK cells, leads to dose-dependent tumor regression Heidelberg, Germany, April 12, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology compa...